MediWound (NASDAQ:MDWD – Get Free Report) and Anika Therapeutics (NASDAQ:ANIK – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Volatility and Risk
MediWound has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.
Institutional and Insider Ownership
46.8% of MediWound shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares MediWound and Anika Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -170.10% | -47.24% | -24.27% |
| Anika Therapeutics | -1.43% | 1.87% | 1.39% |
Analyst Recommendations
This is a breakdown of recent ratings for MediWound and Anika Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 0 | 4 | 0 | 2.60 |
| Anika Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
MediWound currently has a consensus target price of $33.00, indicating a potential upside of 154.43%. Anika Therapeutics has a consensus target price of $22.00, indicating a potential upside of 59.30%. Given MediWound’s stronger consensus rating and higher possible upside, equities research analysts clearly believe MediWound is more favorable than Anika Therapeutics.
Earnings & Valuation
This table compares MediWound and Anika Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $11.86 million | 14.22 | -$23.88 million | ($1.80) | -7.21 |
| Anika Therapeutics | $123.43 million | 1.50 | -$10.88 million | ($0.13) | -106.23 |
Anika Therapeutics has higher revenue and earnings than MediWound. Anika Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.
Summary
Anika Therapeutics beats MediWound on 9 of the 14 factors compared between the two stocks.
About MediWound
MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds. MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.
About Anika Therapeutics
Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
